Burke W.  Whitman net worth and biography

Burke Whitman Biography and Net Worth

Director of Amicus Therapeutics
Mr. Whitman has served as a member of the Board since 2019.  He leads and governs mission-driven organizations in business, national service, and civil society.  Since 2019 he serves as CEO, Colmar Holdings (private); Board of Directors, Amicus Therapeutics; Board of Directors, Omega Healthcare Investors; Board of Advisors, Secretary of Defense (Reserve Forces Policy Board); and Board of Trustees, The Lovett School.  Formerly in business 1988-2008, he served as CEO, HMA (Fortune 500, sold); CFO, Triad Hospitals (Fortune 500, sold); President, Deerfield Healthcare (private, sold); VP, Almost Family; and Investment Banker, Morgan Stanley.  Concurrently in national service 1985-2018, he served as a reserve officer of the U.S. Marine Corps including active duty 1985-1988 and 2009-2018, led five combat deployments, was Commanding General of 4th Marine Division and Marine Forces Reserve, served with the Secretary of Defense, and completed uniformed service as a Major General and the Corps’ senior reservist.  For civil society, he has served on the Boards of the Federation of American Hospitals, Toys for Tots Foundation, Marine Corps University, and on the Founders Group of the National Museum of the Marine Corps.  He is a graduate of Harvard Business School, Army War College, and Dartmouth College.

Mr. Whitman serves as member of the Nominating and Governance Committee and as member of the Audit and Compliance Committee.

What is Burke W. Whitman's net worth?

The estimated net worth of Burke W. Whitman is at least $296,903.24 as of September 1st, 2021. Mr. Whitman owns 25,034 shares of Amicus Therapeutics stock worth more than $296,903 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Whitman may own. Learn More about Burke W. Whitman's net worth.

How do I contact Burke W. Whitman?

The corporate mailing address for Mr. Whitman and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Burke W. Whitman's contact information.

Has Burke W. Whitman been buying or selling shares of Amicus Therapeutics?

Burke W. Whitman has not been actively trading shares of Amicus Therapeutics during the past quarter. Most recently, on Monday, November 1st, Burke W. Whitman bought 1,500 shares of Amicus Therapeutics stock. The stock was acquired at an average cost of $10.49 per share, with a total value of $15,735.00. Learn More on Burke W. Whitman's trading history.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 45 times. They sold a total of 550,299 shares worth more than $7,074,819.11. The most recent insider tranaction occured on March, 5th when Director Margaret G Mcglynn sold 7,500 shares worth more than $100,500.00. Insiders at Amicus Therapeutics own 2.1% of the company. Learn More about insider trades at Amicus Therapeutics.

Information on this page was last updated on 3/5/2024.

Burke W. Whitman Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2021Buy1,500$10.49$15,735.00View SEC Filing Icon  
10/1/2021Buy1,500$9.56$14,340.00View SEC Filing Icon  
9/1/2021Buy1,500$11.41$17,115.00View SEC Filing Icon  
8/2/2021Buy1,500$9.28$13,920.0060,582View SEC Filing Icon  
7/1/2021Buy1,500$9.60$14,400.0059,082View SEC Filing Icon  
6/1/2021Buy1,500$9.24$13,860.0047,467View SEC Filing Icon  
4/1/2021Buy1,500$10.00$15,000.0044,467View SEC Filing Icon  
1/4/2021Buy1,500$23.17$34,755.0039,967View SEC Filing Icon  
12/1/2020Buy1,500$23.50$35,250.0038,467View SEC Filing Icon  
11/2/2020Buy1,500$18.01$27,015.0036,967View SEC Filing Icon  
10/1/2020Buy1,500$14.28$21,420.0035,467View SEC Filing Icon  
9/1/2020Buy1,500$14.62$21,930.0033,967View SEC Filing Icon  
7/1/2020Buy1,500$15.20$22,800.0030,967View SEC Filing Icon  
8/23/2019Buy4,945$10.07$49,796.1521,612View SEC Filing Icon  
See Full Table

Burke W. Whitman Buying and Selling Activity at Amicus Therapeutics

This chart shows Burke W Whitman's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late-onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $11.71
Low: $11.49
High: $11.93

50 Day Range

MA: $12.68
Low: $11.43
High: $14.00

2 Week Range

Now: $11.71
Low: $9.70
High: $14.57

Volume

984,914 shs

Average Volume

3,103,521 shs

Market Capitalization

$3.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77